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Abstract
Background: Conditional expression vectors have become a valuable research tool to avoid
artefacts that may result from traditional gene expression studies. However, most systems require
multiple plasmids that must be independently engineered into the target system, resulting in
experimental delay and an increased potential for selection of a cell subpopulation that differs
significantly from the parental line. We have therefore developed pHUSH, an inducible expression
system that allows regulated expression of shRNA, miRNA or cDNA cassettes on a single viral
vector.
Results:  Both Pol II and Pol III promoters have been successfully combined with a second
expression cassette containing a codon-optimized tetracycline repressor and selectable marker.
We provide examples of how pHUSH has been successfully employed to study the function of
target genes in a number of cell types within in vitro and in vivo assays, including conditional gene
knockdown in a murine model of brain cancer.
Conclusion: We have successfully developed and employed a single vector system that enables
Doxycycline regulated RNAi or transgene expression in a variety of in vitro and in vivo model
systems. These studies demonstrate the broad application potential of pHUSH for conditional
genetic engineering in mammalian cells.
Background
The development of RNA interference (RNAi) as a tool for
reverse genetic studies in mammalian systems has rapidly
matured. After the seminal observation that 21 nucle-
otide, chemically-synthesized RNA duplexes (referred to
as short-interfering RNA or siRNA) are capable of targeted
gene silencing in mammalian cells [1], RNAi has quickly
become a standard technique for functional genetic anal-
ysis. A significant advancement of this technique was the
development of short-hairpin RNA (shRNA) expression
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technology [2,3]. This strategy exploits the defined tran-
scriptional start and termination signals of RNA polymer-
ase III (Pol III) promoters to produce a short, inverted
transcript. These stem-loop RNA transcripts are then proc-
essed within the cell into functional siRNAs and thereby
provide a means for the stable suppression of target genes.
To this end, multiple groups have reported success in
long-term silencing of target genes in engineered cell lines
and mice [4,5].
Nevertheless, several limitations to the current approach
remain. The primary limitation to vector-based shRNA is
posed by constitutive hairpin expression. If the shRNA is
directed against a gene essential to cell growth and sur-
vival, the probability of obtaining a stable line is low, and
in those cell lines that survive, other factors may compen-
sate for shRNA-induced gene knockdown. In both cases,
the relevant phenotype may be obscured [6]. Several
groups have employed inducible shRNA systems to
address these limitations. One class of inducible systems
co-express the tetracycline repressor (TetR) with a modi-
fied Pol III promoter containing one or more TetR oper-
ons flanking the TATA-box such that transcription is
blocked when the TetR is bound to the promoter. The
expression of shRNA within this scenario occurs in the
presence of tetracycline or related analogs [7-14].
Wiznerowicz and Trono introduced a variation to the
above design by fusing the TetR to KRAB, a transcriptional
repression domain from Kox1 [15]. This fusion silences
any promoter within 3 kb of the TetR operon. Therefore,
shRNA transcription from the Pol III promoter containing
a TetR operon may also be monitored by the ability of the
TetR-KRAB fusion to repress the expression of a fluores-
cent reporter gene driven by an additional RNA polymer-
ase II (Pol II) promoter within the same vector [15]. In a
different approach, several labs have developed Cre
recombinase-based systems in which the shRNA pro-
moter is modified to contain a 'floxed' cassette or spacer
such that hairpin expression is activated only upon Cre-
mediated excision [16,17]. In addition to standard or 'first
generation' shRNA design, it has recently been demon-
strated that a primary micro-RNA (miRNA) scaffold can
efficiently deliver a desired shRNA [18,19]. These 'second-
generation' miRNA mimetics can be expressed from Pol II
promoters, allowing the use of established conditional
expression vectors [20,21].
Each of the above classes of regulated shRNA vectors has
specific advantages – from the temporal and reversible
control of the tetracycline-regulated systems to tissue-spe-
cific silencing of Cre-lox vectors in mice. However, a con-
siderable limitation shared by the reported inducible
shRNA systems is that each system relies on a two-plasmid
approach in which the shRNA expression cassette is sepa-
rated from the regulatory module. To address this issue,
we and others have previously reported the successful
integration of a shRNA/miRNA expression cassette with a
tetracycline dependent repressor or transactivator on a
single vector [22-27]. Here we describe the development
of pHUSH (H1 or U6 short hairpin), as a Gateway®-com-
patible, conditional shRNA system in which TetR expres-
sion and operon usage have been optimized on a single
vector. Importantly, we compare a number of different
shRNA and miRNA configurations in transient transfec-
tion assays and show that the pHUSH backbone is effec-
tive at providing regulated expression from both pol II
and pol III promoters, thereby enabling regulated shRNA,
miRNA and protein expression. The versatility of pHUSH
is demonstrated here using a series of in vitro and in vivo
reverse genetic experiments that were designed to validate
the therapeutic relevance of both novel and characterized
oncology targets.
Results
Analysis of shRNA design
As part of our effort to engineer a conditional shRNA
expression system, we compared hairpin stem and loop
parameters to maximize knockdown efficiency. To gener-
ate a robust, quantifiable assay, we created a transcript
fusion between luciferase and Melk, a Ser/Thr kinase that
we have previously described [25]. The entire Melk cDNA
was cloned downstream of the pGL3-Luc stop codon, and
the resulting pGL3-Melk construct was used as a reporter
for shRNA efficacy in transient co-transfection experi-
ments. We first compared several published strategies for
shRNA design based on two target sequences: sh7 (nt
1686–1704) and shB (nt 1917–1935). For both target
sequences, the following series of shRNAs were created for
comparison: N19 – a simple stem-loop design [2], F – a
'frayed' shRNA design employing artificial asymmetry
[28], and mi23 – a shRNA utilizing the miR23 loop
reported to increase cytoplasmic expression [29,30]. The
sequence of each hairpin is presented in additional file 1.
To compare the efficacy of each design, the resulting
shRNA expression constructs were co-transfected with the
pGL3-Melk reporter at several molar ratios and normal-
ized to control hairpin H1-LacZ. As shown in Figure 1A at
a 10:1 ratio of shRNA to pGL3-MELK, luciferase expres-
sion was decreased for both shRNA sequences, regardless
of the hairpin design. The standard N19 design and mi23-
loop shRNAs were highly effective, yielding 65% (H1-sh7-
N19), 75% (H1-sh7-mi23), 90% (H1-shB-N19), and
95% (H1-shB-mi23) knockdown respectively. While we
noticed a modest increase in knockdown efficiency by the
addition of the miR23 loop at a 10:1 ratio of shRNA to
pGL3-MELK, there was no significant increase in efficacy
with the miR23 loop at lower molar ratios of shRNA to
pGL3-MELK (data not shown) as had been previously
reported [30]. For both sh7 and shB, the contribution ofBMC Biotechnology 2007, 7:61 http://www.biomedcentral.com/1472-6750/7/61
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artificial thermodynamic symmetry (shRNA-F) by the
introduction of 'frayed' ends at the 3' end of the sense
strand was detrimental to hairpin efficacy, suggesting that
destabilization of the shRNA stem-loop in this context did
not lead to increased RISC loading of the antisense strand.
As there did not appear to be a reproducible improvement
with modified shRNAs (F or miR23), we have utilized a
N19 shRNA design for the remainder of this study.
Over the course of our study, several labs reported robust
knockdown with miRNA-based vectors [18-21]. Using a
luciferase transcript-fusion construct with murine p53
sequences cloned downstream of the pGL3-Luc stop
codon, we compared the 'first generation' H1-shRNA
(N19) to a 'second-generation' CMV-miRNA-155 vector
[19]. Unlike the N19 shRNA design, the miRNA mimetic
can be expressed as standard pol II transcripts, which are
then processed by the nuclear Drosha, and cytoplasmic
Dicer endonucleases to form a 21–22 nt active siRNA
[31]. To enable this comparison, we generated a vector in
which a modified CMV promoter [32] was used to express
Emerald GFP (EmGFP) and the miRNA mimetic on the
same transcript (CMV/TO-EmGFP-miRNA). To compare
the efficacy of a shRNA versus miRNA design, two effec-
tive miRNAs directed against p53 were converted to H1-
shRNAs by identifying the 21 nt active siRNA within the
miRNA scaffold and then converting these sequences into
conventional shRNA design according to the scheme pre-
sented in Figure 1B. The sequence and structure of these
hairpins is presented in additional file 2. Although the
performance of the CMV/TO-miR and H1-shRNA hair-
pins using the p53-1 sequence were similar, we observed
increased knockdown by CMV/TO-miR relative to the cor-
responding H1-shRNA sequence for the p53-3 sequence
(Figure 1C). At the lowest ratios of miR or shRNA to
reporter (2.5:1 or 5:1), the CMVTO-miR resulted in ~65–
70% knockdown of the luciferase reporter as compared to
only a ~30–50% knockdown with the H1-shRNA (Figure
1C). Removing the EmGFP leader from CMV-miR-p53-1
destroyed the knockdown efficiency of the original con-
struct (Figure 1D), confirming the requirement of a mini-
mal "spacer" sequence between the transcriptional start
site and the miRNA sequence [21]. To summarize, we
have directly compared "first-generation" pol III-shRNA
vectors to "second-generation" pol II vectors using the
same Dicer-product siRNAs. We have found that both vec-
tor formats are functional. However, based on our
observed increase in knockdown efficiency with CMV/TO-
miR for the p53-3 sequence as compared to the corre-
sponding H1-shRNA version, there may be a slight advan-
tage with the miRNA-like systems for certain sequences
under suboptimal expression conditions.
pHUSH vector design and optimization
pHUSH was constructed as described in the Methods
using the pIRES-Puro2 as the backbone vector. Briefly, the
human-β-actin promoter driving the TetR was subcloned
into pIRES-Puro2 to replace the original CMV promoter.
A modified H1 promoter containing a single TetR operon
with a Melk-targeting shRNA cassette was inserted
upstream to the human-β-actin promoter. Using this plas-
mid as the base vector, we generated two additional ver-
sions for analysis: pHUSH-IVS in which a synthetic intron
sequence between the TetR ORF and the IRES was
removed, and pHUSH-IVSTetROpt, in which the original
TetR sequence within pHUSH-IVS was replaced by a TetR
expression cassette that was codon-optimized for expres-
sion in mammalian cells (Figure 2A). To assess the effect
of these modifications on regulated gene silencing, these
constructs were transfected into HEK293 cells that were
stably expressing an EGFP-Melk fusion protein. After
Luciferase-based transient co-transfection experiments to  compare shRNA and miRNA design schemes Figure 1
Luciferase-based transient co-transfection experiments to 
compare shRNA and miRNA design schemes. Knockdown 
studies were performed in duplicate as co-transfections of 
shRNA:pGL3-gene:pRL at the indicated ratio. Firefly luci-
ferase values are divided by renilla values to control for 
transfection efficiency, and all knockdown data are normal-
ized to control hairpins. (A) Comparison of published modifi-
cations to standard H1-shRNA design (F = frayed, miR23 = 
loop derived from miR-23, and N19 = standard pSuper 
shRNA design) directed against the pGL3-MELK reporter. 
Cells were transfected with a 10:1 ratio of the indicated 
shRNA to pGL3-Melk reporter. (B) CMV-miR to H1-shRNA 
conversion scheme. The active 'siRNA' was identified within 
the pol II-miRNA and converted to a standard H1-shRNA 
hairpin (black bars = Drosha and Dicer processing; red = 
guide strand, blue = miR-155 loop, pink = pSuper loop). (C) 
Comparison of H1-shRNA and CMV-miR vectors corre-
sponding to murine p53 sequences transfected at 7.5:1, 5:1 
and 2.5:1 (shRNA:pGL3-mu-p53). (D) The removal of the 
EmGFP leader renders miR-p53-1 non-functional at a co-
transfection ratio of 10:1.BMC Biotechnology 2007, 7:61 http://www.biomedcentral.com/1472-6750/7/61
Page 4 of 14
(page number not for citation purposes)
selection with puromycin, cells were cultured for five days
in the presence or absence of Doxycycline (Dox), and the
level of EGFP-MELK fluorescence was scored by FACS
analysis. The effectiveness of each construct to repress
shRNA expression was assessed by comparing the level of
EGFP-Melk in the absence of Dox to cells containing a
pHUSH construct without a hairpin (empty vector). As
shown in Figure 2B, all three vectors generated the same
level of knockdown in the presence of Dox (filled bars).
However, we found that in the absence of Dox (open
bars), only the pHUSH-IVSTetRopt  pool exhibited full
repression of shRNA expression (column 3, Figure 2B). In
contrast, partial repression (70% of maximal EGFP-Melk)
was obtained with pHUSH-IVS while cells containing the
base pHUSH vector displayed a complete lack of shRNA
repression, as demonstrated by similar levels of EGFP-
Melk in the presence or absence of Dox (Figure 2B – col-
umns 2 and 1, respectively). Because of the reported
strong splicing donor in the 5' HTLV UTR [33], the
removal of the IVS most likely prevented a splicing event
between the UTR and the splice acceptor within IVS result-
ing in the excision of the TetR. The above data suggests
optimal Dox-dependent regulation of shRNA expression
requires maximal TetR protein levels. To test this hypoth-
esis, we compared TetR expression between the original
TetR construct (derived from pcDNA6/TR) and the codon-
optimized variant utilized for pHUSH-IVSTetROpt. As
shown in Figure 2C, there is a two-to-three fold increase
in TetR protein levels with the codon-optimized TetR
(CMV-TetRopt) as compared to the original construct
(CMV-TetRwt). Therefore, we conclude that both TetR
codon optimization and IVS removal are required for a
regulated gene silencing system.
Because of the observed sensitivity to modest changes in
TetR levels, we next focused on further modifying the H1
promoter to ensure complete shRNA repression under
limiting TetR levels. Several groups have shown that
increased regulation can be achieved by inserting multiple
TetR operons throughout the Pol III promoter [9,32,34].
To determine whether we could observe a similar
enhancement of regulation, we modified the original
pShuttle-H1-shRNA plasmid containing a single TetO2
(1×-TetO2) with an additional TetO2 operon upstream of
the TATA box, forming a 2×-TetO2-H1 promoter. Using
pGL3-Melk as a reporter, the 1×- and 2×-TetO2-H1 pro-
moters were co-transfected with increasing amounts of a
CMV-TetROpt expression plasmid in the absence of Dox.
For both shRNA promoter variants, maximal repression
was achieved when the TetR expression construct was sup-
plied in a 10:1 molar excess over the H1-shRNA (Figure
3A, 10:1) while >80% knockdown was achieved in the
absence of TetR (Figure 3A, 0:1). When the TetR expres-
sion plasmid was limited to a 2:1 molar ratio relative to
the H1-shRNA plasmid, nearly maximal shRNA expres-
sion was observed with the 1×-TetO2 construct. In con-
trast, shRNA repression was maintained with the 2×-
TetO2 construct (Figure 3A). These results suggest that the
use of two TetR operons enhance the ability to regulate
shRNA expression when TetR expression is limiting.
To explore the robustness of this system as a stably-inte-
grated construct, we then compared the 1×-TetO2 and 2×-
TetO2 versions of the pHUSH vector to enable regulated
silencing of Melk within mouse embryonic stem (ES)
cells. Murine ES cells were electroporated with pHUSH-
IVSTetRopt  or pHUSH-IVSTetRopt2 × TetO2, containing a
Melk-directed shRNA and then selected in puromycin.
Multiple clones for both versions of pHUSH were identi-
fied exhibiting robust, regulated MELK knockdown (>70–
90%) after 48 h culture in the presence of Dox (additional
pHUSH vector design and optimization (A) Vector diagrams  of the pHUSH vector series Figure 2
pHUSH vector design and optimization (A) Vector diagrams 
of the pHUSH vector series: (1) original pHUSH backbone 
(2) pHUSH-IVS in which the synthetic intron sequence 
between the TetR ORF and the IRES is removed, and (3) 
pHUSH-IVSTetROpt with a codon-optimzed TetR (B) 
Increased TetR expression ensures regulation of GFP-Melk 
fusion protein in the absence of doxycycline. HEK 293 cells 
expressing a GFP-MELK fusion were transfected with the 
pHUSH vector series described above all containing the shB 
Melk targeting shRNA. After selection with 3 μg/ml puromy-
cin, the resulting stable pools were cultured in the absence 
(open bars) or presence (filled bars) of 1 μg/ml doxycycline 
for five days and GFP-Melk expression analyzed by FACS. 
Data is normalized to the mean fluorescence intensity 
(10,000 acquired events) for cells containing a pHUSH empty 
vector control. A representative experiment is shown. (C) 
Codon optimization of TetR open reading frame (ORF) 
increases translation. Both the original (WT) and codon-opti-
mized (OPT) TetR ORFs were transiently expressed in 293T 
cells. Forty-eight hours post-transfection, cell lysates were 
prepared and Western blotted with an anti-TetR antibody 
and an anti-tubulin antibody.
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file 3). To determine whether regulated shRNA expression
could be maintained upon differentiation, select ES cell
clones (A6 and 3C11) were allowed to differentiate into
embryoid bodies (EBs) by standard methods. EB forma-
tion was induced and cultured in the presence or absence
of 1 ug/ml Dox for 14 days, and endogenous Melk RNA
levels were quantified by qRT-PCR. As shown in Figure 3B,
near maximal silencing of Melk expression was observed
with EBs derived from pHUSH-IVSTetRopt (1×-TetO2, clone
A6) without DOX, indicating no functional repression of
shRNA expression. In contrast, EBs derived from pHUSH-
IVSTetRopt2×-TetO2 (2×-TetO2, clone 3C11) maintained a
similar level of Dox-dependent regulation as had been
observed with the parental, non-differentiated ES cells
(additional file 3). Consistent with these results, we
observed a 3-fold decrease in TetR expression upon differ-
entiation into EBs (data not shown). Although the overall
level of Melk knockdown is reduced within the differenti-
ated EB derived from the 2×-TetO2 promoter relative to
the 1×-TetO2 version (Figure 3B), this difference is likely
due to clonal variations during ES cell selection rather
than an inherent difference in transcriptional strength of
the modified H1 promoter. This is supported by the fact
that the knockdown efficiency between the 1× and 2×
TetO2 constructs is the same when expressed in the
absence of TetR (Figure 3A). In summary, the presence of
multiple TetR operons within the H1 promoter does not
significantly effect maximal shRNA expression while pro-
moting Dox regulated gene silencing even under limiting
TetR expression levels.
pHUSH Retroviral Vectors
To enhance the stable delivery into cultured cells, the
pHUSH-IVSTetRopt2×-TetO2  described above was sub-
cloned into the pQCXIP retroviral backbone to form
pHUSH-Retro. The resulting viral pHUSH plasmid was
converted to a Gateway®-compatible vector to enable effi-
cient transfer of shRNA cassettes between vectors. To com-
pare the ability to conditionally express shRNA or miRNA
using the retroviral backbone, the H1–2 × Tet02 and
CMV-TO vectors containing p53 shRNA or miRNA,
respectively, were introduced into the pHUSH-Retro-Puro
backbone by Gateway® recombination (Figure 4A). Viral
supernatants of pHUSH-Retro were prepared as described
in the Methods and used to infect 3T3 cells at a multiplic-
ity of infection of about 0.2. Cells were selected in 1.5 ug/
mL puromycin and then cultured in the presence or
absence of 1 ug/mL Dox for four days. Interestingly, both
CMV-miR-p53 vectors were more effective than the corre-
sponding H1-shRNA vectors (Figure 4B). Consistent with
the transient transfection results (Figure 1C) the p53-1
sequence was more effective than p53-3. Moreover, these
results indicate that inducible and stable target gene at a
single copy can be achieved by employing 'second gener-
ation' CMV-miR hairpin design and are in agreement with
previous reports [20,21]. It is important to note, however,
that robust silencing using the H1-shRNA vectors can be
achieved presumably as the result of multiple integrations
per cell (Figure 3 and [25,26]). A simple strategy we have
found for maximizing the level of silencing when using
the H1-shRNA pHUSH vectors is to escalate the selection
pressure downstream of the TetR (additional file 4)
Finally, we also provide evidence that regulated protein
expression can be achieved using the pHUSH backbone.
For this purpose, the EmGFP-miR sequence of CMV-TO-
EmGFP-miRNA was replaced by EGFP or EGFP-MELK-
D150A, a previously described kinase-dead MELK variant
[25] fused to the C-terminus of EGFP. pHUSH protein
vectors were completed by Gateway® cloning, retroviral
stocks were generated by standard methods, and HCT116
cells were serially infected and selected at 5 ug/mL puro-
mycin for two weeks. The resulting stable cell lines were
treated ± 1 ug/mL Dox for 72 h. EGFP or EGFP-MELK-
D150A expression was analyzed by direct fluorescent
imaging of a non-reducing polyacrylamide gel (Figure
4C), and western blotted for tubulin to confirm equal
Multiple TetO2 operons within the Pol III promoter enhances  regulated knock-down Figure 3
Multiple TetO2 operons within the Pol III promoter enhances 
regulated knock-down. (A) 293T cells were transfected with 
15 ng of pGL3-huMelk in the presence of decreasing molar 
ratios of TetR and the appropriate H1-shRNA vectors using 
the indicated molar ratio of TetR:H1-shRNA vector. The 
maximal level of gene knockdown that can be observed with 
either promoter is represented by cells transfected with the 
appropriate H1-shRNA vector and no TetR (0:1). Both H1-
shRNA constructs expressed the shB Melk targeting shRNA. 
Luciferase expression was measured as described in the 
Methods 48 hours post transfection. (B) Dox regulated Melk 
knockdown is maintained in differentiated ES cells with the 2 
× TetO2 promoter configuration. Embryoid bodies were gen-
erated as described in the Methods from stable pHUSH ES 
cell clones with shRNA targeting MELK or Luciferase. 
shMELK ES cell lines were generated with either one TetO2 
(1×-TetO2, colony A6) or two TetO2 (2×-TetO2, colony 
3C11) operons (see also additional file 3). ES cells lines were 
differentiated into embryoid bodies in the presence or 
absence of 1 ug/ml doxycycline and the level of Melk expres-
sion determined by qRT-PCR and normalized to the house-
keeping gene SPF31 (RefSeq NM_014280).
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loading. The results indicate that inducible expression of
the proteins can also be achieved with this vector configu-
ration and has in fact been successfully employed to con-
ditionally express a temperature-sensitive mutant of the
GTPase dynamin-1 [35]. We conclude that the retroviral
pHUSH vector is capable of inducible pol III-shRNA
expression, pol II-miRNA expression, and pol II-protein
expression. At present, we have generated destination
pHUSH backbones with the selectable markers as summa-
rized in additional file 6.
In Vivo shRNA Knockdown by pHUSH
To demonstrate the utility of pHUSH as a technology by
which to interrogate the role of a target gene within rele-
vant tumor models in vivo, we constructed a retroviral
pHUSH vector with a luciferase-directed shRNA using the
H1-TetO2 promoter. Retroviral stocks were prepared as
before, and luciferase-expressing SVT2 cells were trans-
duced and selected in 2 ug/mL puromycin. We identified
multiple clones that exhibited high luciferase expression
without Dox and significant knockdown of luciferase
expression in vitro (data not shown). A single clone (SVT2
shLuc.pGL3-B3) expressing on average ~200 relative light
units per ug of total protein in the absence of Dox and dis-
playing ~60% Dox induced knockdown was selected for
in vivo modeling experiments. To this end, immunodefe-
cient nu/nu mice were injected subcutaneously with 1 ×
106 cells of SVT-shLuc.pGL3-B3. After tumors had reached
250 mm3, the animals were separated into the appropriate
Dox treatment group. Tumor growth and luciferase
expression were monitored as described in Methods. As
shown in Figure 5a and 5b, control animals treated with
sucrose water rapidly formed tumors with high luciferase
expression, while those dosed with 400 μg/ml Dox in the
drinking water maintained rapid tumor growth with low
luciferase expression. These studies indicate that func-
tional, Dox regulated shRNA expression can be achieved
in vivo with no discernable indirect effects on tumor
growth or animal health.
We then proceeded to test if inducible, shRNA-mediated
knockdown of reporter gene expression in an orthotopic
brain tumor model could be achieved. Unlike conven-
tional subcutaneous xenograft models that can be moni-
tored by caliper measurement, accurate in vivo
quantitation of intracranial tumor growth necessitates the
use of non-invasive imaging techniques. Both MRI and
bioluminescence imaging have been previously estab-
lished as particularly well suited to the monitoring of gli-
oma progression in vivo [36]. Since Dox and luciferin have
been previously reported to freely cross the brain-blood
barrier, we decided to test whether combining shRNA
knockdown and biolumenscent imaging may be a
method to expedite target validation studies in these more
complex tumor models. To this end, SVT2-shLuc.pGL3-3
cells were injected intracranially and tumor growth and
luciferase expression was monitored as described in Meth-
ods at days 3, 5, and 9 post Dox treatment. We observed
Dox mediated knockdown at a day 3 (9.5-fold), day 5
(13.8-fold) and at day 9 (11-fold) (Figure 5c). Tumor size
at day 9 as quantitated by luciferase expression strongly
correlated with tumor volume as measured ex-vivo by
ultrasound (data not shown). Representative images for
both subcutaneous and orthotopic experiments are
present in additional file 7. These data validate the effec-
tiveness of the pHUSH inducible shRNA system in an
orthotopic mouse brain tumor model.
We next sought to combine knockdown of a relevant
oncogene with bioluminescence imaging (BLI) within
Retroviral delivery of the pHUSH system allows the inducible  expression of shRNA, miRNA or proteins Figure 4
Retroviral delivery of the pHUSH system allows the inducible 
expression of shRNA, miRNA or proteins. (A) Vector dia-
gram of the pHUSH retroviral system. Inducible pol II or pol 
III expression cassettes are introduced by Gateway® recom-
bination. (B) Improved p53 knockdown by CMV-miRNA in 
comparison to H1-shRNA vectors at low MOI. H1-shRNA 
and CMV-miRNA vectors with hairpins designed against 
murine p53 as described in additional file 2 were cloned into 
the pHUSH retroviral backbone. 3T3 cells were infected at 
an MOI = 0.2, selected in 1.5 ug/mL puromycin, and cultured 
± 1 ug/mL Dox, Knockdown of p53 was determined by qRT-
PCR at Day 4 post-Dox and was normalized to p53 levels in 
the absence of Dox. (C) Inducible expression of proteins by 
the pHUSH retroviral system. Inducible EGFP and EGFP-
MELK-D150A expression cassettes were cloned into the 
pHUSH retroviral backbone. HCT116 cells were infected 
with the appropriate viral construct, selected in 5 ug/mL 
puromycin, and treated ± 1 ug/mL Dox for 72 h. Equal total 
protein was fractionated by non-reducing SDS-PAGE and 
imaged by the Typhoon fluorescent imager at the indicated 
excitation and emission spectra (WB = western blot). Equal 
loading was confirmed by western blotting with an anti-tubu-
lin antibody.BMC Biotechnology 2007, 7:61 http://www.biomedcentral.com/1472-6750/7/61
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tumor models in vivo. We have previously generated and
characterized retroviral pHUSH vectors with multiple B-
raf-directed shRNAs. B-Raf, a serine/threonine kinase, is
mutated in 70% of melanomas [37] and has been pro-
posed as a candidate small molecule therapeutic target
[38]. We have previously provided data in support of this
proposal by demonstrating the requirement of this kinase
within several tumor growth models [26] by employing
pHUSH to knockdown the expression of B-Raf in human
melanoma cell lines. We have since continued to deplete
oncogenic B-Raf in multiple settings and now provide
additional data to further demonstrate how this technol-
ogy may be applied. As shown in Figure 6A, we were suc-
cessful at generating and identifying clones with Dox-
dependent silencing of B-Raf in A375 cells, a human
tumor cell line derived from a malignant cutaneous
melanoma. We also observed an inhibition of B-Raf sign-
aling upon silencing, demonstrated by a decrease in phos-
pho-Erk1/2 levels. As expected, the consequence of B-raf
knockdown and MAPK pathway modulation is evident by
a decrease in proliferation under low serum, as well as a
Dox-dose dependent decrease in VEGF secretion in vitro
(Figures 6B and 6C).
To establish a method to non-invasively monitor BRAF
silencing within the context of a tumor model in vivo, a
LOX-IMV1 melanoma line with the pHUSH-Braf-shRNA
[26] was re-engineered to express a Luc-BRAF transcript
fusion. Dox-regulated luciferase expression was observed
in several LOX-IMV1 pHUSH lines as indicated by the
depletion of Luc-B-Raf fusion in vitro by a luciferase assay
(additional file 8). We then performed an in vivo tumor
growth study by subcutaneously inoculating Scid-beige
mice with 1 × 106 cells of LOX-IMV1 shBraf.pGL3-Braf
clone A1. After tumors had reached 250 mM3, the animals
were separated into the appropriate Dox treatment group,
Effective in vivo silencing of luciferase in subcutaneous and intracranial tumor models Figure 5
Effective in vivo silencing of luciferase in subcutaneous and intracranial tumor models. (A) Mean intensity luciferase expression 
indicates Dox induced luciferase knockdown in subcutaneous tumor xenograft at day 3 and 5 post-injection. Eight animals are 
represented for each treatment condition. (B) Dox treatment or luciferase knockdown does not reduce tumor growth of 
SVT2 cells in SCID mice. (C) Mean intensity luciferase expression demonstrates Dox-induced luciferase knockdown relative to 
controls at days 3 (9.5 fold), 5 (13.8 fold) and 9 (11 fold) post-injection. The luminescence values for each time point have been 
normalized to the respective intensity value at day 0. Five animals are represented for each treatment condition. Representa-
tive BLI images are shown in additional file 7.
AB
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and tumor growth and luciferase expression were moni-
tored. As shown in additional file 9, control animals
treated with sucrose water rapidly formed tumors, while
those dosed with 500 μg/ml Dox had complete tumor
remission according to caliper measurements of tumor
volume. We have previously demonstrated that the in
vivo tumor growth of LOX-IMV1 cells, engineered to
express a luciferase targeting shRNA, are not affected by
Dox treatment [26]. Therefore the observed tumor remis-
sion upon Dox treatment is due to Braf silencing and not
the result of an off-target effect of Dox treatment. Animals
treated with 20 μg/ml Dox exhibited growth stasis, while
those treated with 10 μg/ml Dox resulted in an approxi-
mately 20% decrease in tumor growth relative to sucrose
control animals. By measuring luciferase expression, a
robust decrease in signal was measured at 500 μg/ml
(98%) and a moderate decrease at 20 μg/ml Dox (62%) in
comparison to the control or 10 ng/uL Dox treated ani-
mals (Figure 6D). Tumors were harvested at day 25 and in
vivo  Luc-Braf knockdown was confirmed in harvested
tumor lysates by a luciferase assay, confirming the utility
of this strategy to monitor as well as titrate target gene
knockdown in vivo (Figure 6E).
Discussion
We report the development of an inducible shRNA system
that is delivered on a single plasmid or viral vector. By uti-
lizing a reporter such as the pGL3-MELK construct,
numerous shRNAs designed against a particular gene or
genes can be screened, and effective hairpins can be rap-
idly cloned by Gateway® recombination into the appropri-
ate pHUSH destination vector. "First generation" pol III-
shRNA vectors, "second generation" pol II-miRNA, and
protein expression vectors have been successfully devel-
oped as components for inducible expression on several
backbones. Silencing is robust and titratable for both in
vitro and in vivo experimental models.
The described pHUSH system is based on the native Tet
repressor instead of the TetR-VP16 fusion protein. Because
regulation is based on repression of a modified active pro-
moter rather than the transactivation of a minimal pro-
moter, the required components are reliably expressed as
a single construct. By combining the shRNA and TetR
expression cassettes on the same plasmid or virus, we have
dramatically decreased the time required to generate sta-
ble cell pools or clones exhibiting the desired level of reg-
ulated RNAi. Since we have not directly compared the
pHUSH vector with other inducible shRNA, miRNA or
protein expression systems, we cannot conclude if our
vector design represents a major improvement over exist-
ing systems. However, by directly comparing the expres-
sion strategies of individual pHUSH vector components
by a variety of cell-based assays, we can conclude that a
single-plasmid vector system that combines miRNA
expression, multiple TetR operons and a codon-opti-
mized TetR is highly reliable for routine cell line engineer-
ing.
The ability to perform in vitro or  in vivo RNAi high-
throughput screens (HTS) may also be possible with the
pHUSH system. This approach is based on the delivery of
a large pool of shRNA or miRNAs designed against thou-
sands of genes [5,39,40]. Several large, vector-based RNAi
libraries now exist. Two are based on the first generation
polIII-shRNA design [41,42], and one is based on a miR
scaffold [18]. Recently a conditional shRNA library target-
ing approximately 2,500 genes and utilizing a two vector
approach for inducible shRNA screens has been success-
fully employed [14]. It is therefore conceivable that that
an effective single vector shRNA or miRNA conditional
library could be based on the pHUSH system. Moreover,
this combined system could also be used for direct in vivo
application of inducible RNAi vectors for gene therapy
Robust and titratable depletion of oncogenic B-Raf in  melanoma tumor lines elicits the expected phenotypes in  vitro and in vivo Figure 6
Robust and titratable depletion of oncogenic B-Raf in 
melanoma tumor lines elicits the expected phenotypes in 
vitro and in vivo. (A) Knockdown of BRAF at Day 2 upon Dox 
addition as determined by western blotting in A375 cells. 
BRAF knockdown results in a significant reduction in phos-
pho-ERK levels. (B) Proliferation assay reveals a growth stasis 
phenotype upon BRAF knockown in comparison to a shEGFP 
control in A375 cells. (C) Dose dependent decrease in VEGF 
secretion correlates with BRAF knockdown 24 and 48 h post 
Dox addition. (D) In vivo BRAF knockdown detected by non-
invasive bioluminescence imaging. A previously characterized 
LOX-IMV1 clone containing pHUSH-Braf-shRNA [26] was 
re-engineered to express a Luc-BRAF transcipt fusion. After 
initiating a subcutaneous tumor model in Scid-beige mice, the 
expression level of a Braf targeting shRNA was indirectly 
monitored by bioluminescence imaging at 0, 0.01 mg/mL, 
0.02 mg/mL, and 0.5 mg/mL Dox. (E) Day 25 tumors were 
harvested and equal total protein was assayed for luciferase 
enzyme activity in vitro.
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studies or for inter-tumoral target validation in cancer
mouse models.
By combining inducible shRNA technology with biolumi-
nescence imaging, large in vivo experiments can be per-
formed without the use of traditional caliper
measurements [43]. We have previously demonstrated the
utility of our approach by measuring the effect of onco-
genic B-Raf depletion in a mouse model of metastatic
melanoma. Pulmonary tumor burden was quantified by
in vivo luciferase expression without animal dissection,
thereby enabling measurements of disease progression
over time in the same animal [26]. For the study presented
in this report, endogenous B-Raf depletion was tracked by
engineering a luceriferase-based reporter in which B-raf
was cloned downstream of the luciferase stop codon. We
demonstrate robust in vivo B-raf knockdown as detected
by the decrease in luciferase signal while maintaining the
reported tumor regression phenotype for endogenous B-
Raf knockdown in this model.
One of the primary challenges to targeted cancer thera-
peutics is tumor escape mediated by drug resistance as in
the case of Gleevec [44]. Inducible and reversible shRNA
expression systems such as pHUSH may be utilized for
tumor outgrowth or "Dox cycling" experiments in which
tumors regress upon shRNA-mediated oncogene knock-
down, acquire the ability to evade oncogene knockdown,
and then progress as a resistant tumor [45]. The exoge-
nous luciferase reporter allows the integrity of regulated
gene silencing to be checked, ensuring that knockdown is
maintained and that tumor escape is not simply caused by
the loss of regulated shRNA expression. This approach,
therefore, may be suited for tumor studies to model novel
mechanisms of cancer resistance as well as identify new
pathways for tumorigenesis. Importantly, our approach is
also effective in a mouse model for brain cancer.
Several important in vivo applications for a single plasmid
or viral vector system are not presented in this report. The
question remains if the system would function as a germ-
line-integrated cassette in adult mice. By engineering a
second Tet operon in the H1 promoter, we have achieved
regulated shRNA expression in embryoid bodies. The 2×-
TetO2 H1 promoter exhibited total regulation of shRNA
expression under differentiated conditions and decreased
TetR levels. Although we have carefully optimized TetR
translation by codon-optimization and TetR expression
by selecting a promoter associated with strong and ubiq-
uitous expression in multiple tissue and cell types, it is
unclear whether the current vector configuration will yield
transgenic mice with regulated shRNA expression in all
tissues. However, the potential for the direct, in vivo appli-
cation of a single viral vector system for inducible shRNA
expression exists due to the co-integration of both the
shRNA and TetR cassettes.
Conclusion
The flexibility of the pHUSH to inducibly express shRNA,
miRNA and proteins on a variety of plasmid and viral
backbones will enable rapid target validation in a diverse
array of in vitro and in vivo systems.
Methods
Cell Lines and antibodies. HCT116, SVT2, LOX-IMV1,
and A375 cells lines were maintained as previously
reported [25,26]. 293T, 293HEK and NIH3T3 cells were
obtained from American Type Culture Collection (Manas-
sas, VA) and maintained at 37°C and 5% CO2 in DMEM
with 10% tetracycline-free fetal bovine serum (Clontech,
Palo Alto, CA) supplemented with 2 mM L-glutamine,
100 mM Hepes, and 100 U/ml penicillin/streptomycin.
Anti-γ-tubulin, anti-BRAF, anti-phospho-Erk1/2, and anti-
Erk2 antibodies were used for western blotting as previ-
ously described [26]. Monoclonal mouse IgG1 mix anti-
TetR antibody was purchased from MoBiTec (Göttingen,
Germany).
Generation of transgenic ES cell lines and ES cell in vitro
differentiation. ES cell culture medium was made of Dul-
becco's modified Eagle medium (DMEM), supplemented
with 15% heat-inactivated fetal calf serum, 2 mM L-
glutamine, 0.1 mM non-essential amino acids, 1000 IU/
ml recombinant human leukemia inhibitory factor (LIF;
ESGRO), 0.1 mM b-mercaptoethanol, 50 U/ml penicillin,
and 50 ug/ml streptomycin. To generate transgenic ES cell
lines, 1 × 107 of R1 ES cells were electroporated with 20 μg
of linearized vector DNA and selected in ES cell culture
medium containing 1–1.5 μg/ml puromycin. ES cell dif-
ferentiation medium was made of Dulbecco's modified
Eagle medium (DMEM), supplemented with 10% heat-
inactivated fetal calf serum, 50 U/ml penicillin, and 50
ug/ml streptomycin. For in vitro differentiation, ES cells
were first cultured in ES cell medium in hanging drops
(600 cells/30 μl/drop) for one day and then in differenti-
ation medium in suspension as embryoid bodies in bac-
teriological petri dishes for 7 days. Embryoid bodies were
then transferred to tissue culture plates coated with 0.1%
gelatin for continuous culture in differentiation medium.
Colonies with beating cardiomyocytes were visually
scored at 14–17 days post-induction of EB differentiation.
Vector Construction. The TetR gene was codon-optimized
for mammalian expression using the DNAWorks program
[46]. Using a compatible end derived from a BsaI site, we
ligated either the codon-optimized TetR or a PCR product
encoding the original open reading frame of pcDNA6/TR
(Invitrogen, Carlsbad, CA) in-frame to the NcoI start site
of pDRIVE-5'RU (Invivogen, San Diego, CA). The humanBMC Biotechnology 2007, 7:61 http://www.biomedcentral.com/1472-6750/7/61
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β-actin TetR cassette was then PCR amplified using Pfu
Turbo Polymerase (Stratagene, La Jolla, CA), adding a four
restriction site 'polylinker' (MfeI,  ClaI,  SpeI,  AgeI)
upstream of the promoter, and was subcloned into pIRES-
Puro2 (Clontech, Palo Alto, CA) using MfeI and EcoRI
sites to form EV-pHUSH. Due to the possibility that 5'
UTR of the human β-actin cassette harbored a splicing
donor that may form an intron with the intervening
sequence (IVS) [47] derived from pIRES-Puro2, we
removed the IVS sequence by swapping the original IVS-
IRES-Puro module with a related IRES-Puro fragment
derived from pQCXIP (Clontech, Palo Alto CA).
shRNA hairpin shuttle vectors were constructed by PCR
sub-cloning the pSuperior-H1 promoter (OligoEngine,
Seattle, WA), adding XbaI, SpeI, and AgeI sites, and then
TOPO-cloning into pENTR/D (Invitrogen) to form pShut-
tle-H1-shRNA. In order to introduce hairpin sequences,
pShuttle-H1-shRNA was linearized by cutting with BglII
and HindIII, and hairpin inserts were generated by synthe-
sizing complementary 5'-phosphorylated DNA oligonu-
cleotides, which were annealed in 100 mmol/L potassium
acetate, 30 mmol/L HEPES-KOH (pH 7.4), and 2 mmol/
L magnesium acetate for 3 minutes at 95°C followed by 1
hour at 37°C. The resulting dsDNA fragment was ligated
into pShuttle-H1-shRNA and confirmed by sequencing. A
similar strategy was employed to add a second TetO2
operon to form pShuttle-H1-shRNA-2×-TetO2 by ligating
dsDNA into the MslI and HindIII sites of the orginal vec-
tor. H1-shRNA cassettes were subcloned into the pHUSH
backbone by ligating the XbaI-AgeI fragment from pShut-
tle-H1-shRNA into the compatible SpeI-AgeI site of the
pHUSH backbone to form the complete non-viral
pHUSH vectors as presented in Figures 2 and 3.
The protein expression cassette was generated by PCR
amplifying pcDNA4/TO, and the resulting product was
TOPO-cloned into pENTR/D to form pShuttle-CMV/TO.
To generate the inducible protein expression cassettes pre-
sented in Figure 4, an AgeI (blunted with T4 polymerase)-
EcoRI fragment from EGFP-C1 (Clontech, Palo Alto CA)
was ligated to pShuttle-CMV/TO, which was prepared by
cutting with PmeI and EcoRI to form pShuttle-CMV/TO-
EGFP. To generate pShuttle-CMV/TO-EGFP-MELKD150A,
the NheI-XbaI fragment comprising EGFP-MELKD150A was
cloned into the XbaI site of pShuttle-CMV/TO.
The inducible CMV-miR cassette was constructed by sepa-
rately PCR amplifying pShuttle-CMV/TO and pmi6/
EmGFP-miR-neg (Invitrogen, Carlsbad CA). Since these
PCR products were designed to overlap each other, they
were pooled and subjected to a second round of PCR,
which resulted in ligation of the two products. The result-
ing PCR product was TOPO-cloned into pENTR/D (Invit-
rogen, Carlsbad CA) to form pShuttle-CMV/TO-miR. The
original miRNA was replaced by ligating dsDNA oligos
designed to restore the original sequence and maintain
the appropriate overhangs for the introduction of new
miRNA sequences. miRNAs were introduced by lineariz-
ing the vector with BsaI.
To prepare the completed pHUSH retroviral vector uti-
lized in Figures 4, 5, 6, 7, the BglII-EcoRI fragment of EV-
pHUSH was subcloned into the retroviral vector pQCXIP,
replacing the CMV promoter. The Gateway® acceptor read-
ing frame cassette B (Invitrogen, Carlsbad CA) was ligated
to the MfeI site, which was blunted by T4 polymerase,
directly upstream of the human β-actin promoter to gen-
erate the final, Gateway®-compatible retroviral pHUSH
system. Gateway® cloning and plasmid propagation was
preformed according to the manufacturer's recommenda-
tions.
The pGL3-Luciferase reporter vectors were generated by
first ligating to the XbaI site of pGL3-Luc (Promega, Mad-
ison, WI) a mutiple cloing site downstream of the luci-
ferase stop codon to form pGL3-Luc-MCS. pGL3-MELK,
pGL3-BRAF or pGL3-p53 vectors were constructed by
ligating the entire cDNA of MELK or BRAF into pGL3-Luc-
MCS, or, in the case of pGL3-Luc-p53, long synthesized
dsDNA. All oligonucleotide sequences employed in the
generation of these vectors are available upon request.
H1-shRNA and CMV-miR hairpin selection and
sequences. H1-shRNA hairpin sequences were either iden-
tified in previous reports, selected by standard 'Tuschl'
rules [1], or custom designed by Dharmacon (Lafayette,
CO). 19 bp core targeting sequences were converted to
clonable dsDNA sequences with the aid of the program
tohairpin (Colin Wanatabe, Genentech) and ordered as
DNA oligonuceoltides. CMV-miR hairpins were designed
using the BLOCK-iT RNAi Designer (Invitrogen, Carlsbad
CA). Hairpin sequences for MELK, BRAF and luciferase
were previously described [25,26]. For Melk knock-down
in murine ES cells, (Figure 3B and Supplement Figure S3),
the following DNA oligonucleotides were used: shMELK-
Q1 (sense) 5'-GAT CCC CCG TGG ACT TCG TAC AGA
AAT TCA AGA GAT TTC TGT ACG AAG TCC ACG TTT TTT
GGA AA-3' and (antisense) 5'-GC TTT TCC AAA AAA CGT
GGA CTT CGT ACA GAA ATC TCT TGA ATT TCT GTA
CGA AGT CCA CGG GG-3'. Annotated shRNA and
miRNA sequences used in Figures 1 and 4 are described in
additional files 1 and 2.
Viral packaging and cell line generation. Retroviral pack-
aging and transduction of target cell lines were prepared as
described previously [25,26]. Briefly, to package retroviral
stocks of pHUSH, AmphoPak cells (Orbigen, San Diego,
CA) were transfected with 8 μg DNA using the CalPhos
Mammalian Transfection kit (Clontech, Palo Alto CA).BMC Biotechnology 2007, 7:61 http://www.biomedcentral.com/1472-6750/7/61
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Supernatants were collected 48 h post-transfection, fil-
tered through a 0.45 μm cellulose acetate filter and added
to the target cell lines. In some cases, target cells were seri-
ally infected at 24 h intervals. Selection with puromycin
began 48 h after the final infection and continued 5–7
days or until the cells were fully selected. After arriving at
a stable pool, the cells were cloned by limiting dilution
and assessed by qRT-PCR for regulated knockdown of the
target gene.
Luciferase Assays. Transfection assays with luciferase assay
endpoints were performed in duplicate or triplicate in 96-
well plates at the plasmid molar ratios as listed in the
results section. 293T or 293HEK cells were transfected
using Lipofectamine 2000 with 200 ng of total DNA with
4 ng of the pRL plasmid, encoding the Renilla luciferase
control, to normalize transfection efficiency between
wells. The Steady-Glo Luciferase Assay System (Promega)
was utilized with the Victor3 Multilabel Counter (Perkin-
Elmer, Wellesley, MA) to quantify firefly and renilla luci-
ferase expression 72 h post-transfection.
Knockdown and Phenotypic Analysis. RNA isolation and
real-time qRT-PCR analysis was performed as previously
described [25,26]. Additional Taqman primer and probe
sequences used in report are murine p53 (forward primer,
5'-CCG CGG GCG TAA ACG-3', reverse primer, 5'-GCA
TGG GCA TCC TTT AAC TCT AA-3', and probe 5'-FAM-
CCT CAT TCA GCT CCC GGA ACA TCT C-BHQ-3') and
murine SPF31 (forward primer, 5'-TGG GAA GCC ATC
CTT GAG-3', reverse primer, 5'-TGA CTG CCG TGT GAA
TCC-3', and probe 5'-FAM-CAA TAC CTC TCC TAT TGG
AGC AAG GGC-BHQ-3'). Fluorescent detection of EGFP
and EGFP-MELKD150A proteins was conducted by fraction-
ating equal total protein by polyacylamide gel electro-
phoresis on a 4–20% Tris-Glycine gel (Invitrogen,
Carlsbad CA) and then imaged with the Typhoon Trio
(GE Healthcare, Piscataway, NJ).
To determine whether attenuation of oncogenic BRAF by
inducible-shRNA knockdown decreases A375 melanoma
cell proliferation, A375 cells expressing either BRAF or
control GFP shRNAs were cultured in 0.1% serum in the
presence or absence of 0.5–1 μg/ml Doxycycline. At 2-day
intervals, viable cell counts were determined by the try-
phan blue exclusion method using a Vi-Cell Analyzer
(Beckman Coulter). Cell numbers are presented as mean
± SD.
The concentration VEGF165–206 was analyzed in cell lysates
homogenized in buffer containing 10 mM Tris, 0.1%
monothioglycerol acetate, and 1.5 mM EDTA (pH 7.4).
The homogenate was then centrifuged for 30 min at
200,000 × g at 4°C and VEGF measured in the resulting
supernatant using quantitative ELISAs. The VEGF165–206
ELISA uses a mouse monoclonal antibody (3.5F8) that
detects exon 7-encoded peptide sequences specific for
VEGF165 for capture and biotinylated A4.6.1 for detection
[48].
Tumor models. Six- to 8-week-old female SCID Beige or
CD-1 Nude mice were purchased from Charles River Lab-
oratories and maintained in accordance to Guidelines for
the Care and Use of Laboratory Animals in our institute's
conventional animal facility. For subcutaneous tumor
models, mice were injected in the right flank with 3 × 106
human LOX-IMVI shRNA-containing cell clones resus-
pended into 200 μL phosphate-buffered saline (PBS).
When tumors reached a mean volume of ~150 mm3 the
mice with similarly sized tumors were grouped into treat-
ment cohorts. Mice received 5% sucrose only or 5%
sucrose plus 0.01, 0.02 or 0.5 mg/ml doxycycline for con-
trol and knockdown cohorts, respectively. All water bot-
tles were changed 3 times per week. Tumors were
measured with calipers and mice weighed twice per week.
Mice whose tumors reach 2000 mm3 were euthanized. At
the end of the dosing study, or as indicated, appropriate
tumor samples were taken. Between 3–4 mice were used
for each treatment group and results are presented as
mean tumor volume ± SEM.
Intracranial implantation. Cells were harvested in mid-log
phase and resuspended in Hank's buffer. CD-1 nude mice
were anesthetized with 2% isoflurane and placed into the
stereotactic apparatus before exposure of the cranium
with a midline incision. A less than 1 mm burrhole was
drilled through the parietal bone. 2.5 × 105 cells in 5 μl
were injected in the right striatum at coordinates from the
bregma 0.5 mm posterior, 2.0 mm lateral, and 3.5 mm
intraparenchymal over 5 minutes using 10 ul Hamilton
syringe with a 27 g stainless steel cannula. The incision
was closed with suture.
Bioluminescence imaging
Mice were imaged using the following procedure to mon-
itor doxycycline mediated knockdown. Prior to image
acquisition, tumor-bearing mice were anesthetized using
isoflurane and injected intraperitoneally with 200 mg/kg
D-luciferin (Invitrogen; Carlsbad, California) in 250 μL
volume. During image acquisition the mice were placed
in a light-tight imaging chamber and maintained on iso-
flurane anesthesia via nose cone delivery and body tem-
perature was regulated using a warming pad.
Bioluminescence images were acquired using a cooled
intensified charge-coupled device camera. Image acquisi-
tion times varied according to signal intensity but were
typically less than 1 second for the subcutaneous model
with longer integration times used for the intracranial
model. Signals were localized by overlaying a reference
image of the mouse with the bioluminescence data image.BMC Biotechnology 2007, 7:61 http://www.biomedcentral.com/1472-6750/7/61
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Images were quantitated by evaluating pixel intensities in
the bioluminescence data image, applying an appropriate
background correction and scaling the resulting values to
account for variations in acquisition time and camera set-
tings to give a mean intensity in relative light units (RLU)
that could be further analyzed to discern the effects of
doxycycline mediated luciferase knockdown.
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of a luciferase-Braf transcript fusion in shCom-4-pHUSH LOX-IMV1 
clones.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1472-
6750-7-61-S8.ppt]
Additional file 9
In vivo tumor growth of shCom-4-pHUSH LOX-IMV1 cells engineered 
with the luciferase-Braf shRNA reporter. Correlation between calliper and 
BLI measurements validate the utility of the luciferase reporter as a 
method for quantifying in vivo tumor growth.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1472-
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